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A B S T R A C T
Background: Poorly healing wounds are one of the major complications in patients suffering from
recessive dystrophic epidermolysis bullosa (RDEB). At present, there are no effective means to analyze
changes in cellular and molecular networks occurring during RDEB wound progression to predict wound
outcome and design betted wound management approaches.
Objectives: To better define mechanisms influencing RDEB wound progression by evaluating changes in
molecular and cellular networks.
Methods: We developed a non-invasive approach for sampling and analysis of wound-associated
constituents using wound-covering bandages. Cellular and molecular components from seventy-six
samples collected from early, established and chronic RDEB wounds were evaluated by FACS-based
immuno-phenotyping and ELISA.
Results: Our cross-sectional analysis determined that progression of RDEB wounds to chronic state is
associated with the accumulation (up to 90 %) of CD16+CD66b+ mature neutrophils, loss of CD11b+CD68+
macrophages, and a significant increase (up to 50 %) in a number of CD11c+CD80+CD86+ activated
professional antigen presenting cells (APC). It was also marked by changes in activated T cells populations
including a reduction of CD45RO+ peripheral memory Tcells from 80 % to 30 % and an increase (up to 70 %)
in CD45RA+ effector T cells. Significantly higher levels of MMP9, VEGF-A and cathepsin G were also
associated with advancing of wounds to poorly healing state.
Conclusions: Our data demonstrated that wound-covering bandages are useful for a non-invasive
sampling and analysis of wound-associated constituents and that transition to poorly healing wounds in
RDEB patients as associated with distinct changes in leukocytic infiltrates, matrix-remodeling enzymes
and pro-angiogenic factors at wound sites.
© 2020 The Author(s). Published by Elsevier B.V. on behalf of Japanese Society for Investigative
Dermatology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Hereditary recessive dystrophic epidermolysis bullosa (RDEB)
is a mechanobullous disease characterized by the fragility of the
skin and development of blisters and erosions following minor
stress to the skin. The disease is caused by mutations in the Col7A1
gene, which result in a lack or dysfunction of type VII collagen
(Col7), the exclusive structural component of anchoring fibrils, at
the dermal-epidermal junction (DEJ) [1]. Separation of skin layers
leads to the development of lesions ranging from skin blisters to
chronic ulcerated wounds. RDEB skin wounds are often associated
with numerous complications, including pain and itch, loss of
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fluids and nutrients, infection, sepsis, dehydration, extensive
scarring, deformities of the hand and feet, and cancer, thus,
presenting a major health-related burden for RDEB patients [2].
At present, there are no objective means to predict the wound
outcome in RDEB. Wound healing is a well-orchestrated process
with rather distinct phases of hemostasis, inflammation, prolifer-
ation and maturation [3]. Prolonged and de-regulated inflamma-
tory stage is often associated with compromised healing and
progression to chronic wounds [4], which are often observed in
RDEB [5]. In RDEB patients, skin lesions frequently occur at sites of
most mechanical stress (knees, feet, hands, and elbows). RDEB
wounds also often colonized with pathogenic bacteria, leading to
excessive inflammation and affecting healing [6]. Although
substantial clinical data regarding RDEB wounds have been
accumulated over the years, there is still a substantial gap in
our understanding of the molecular and cellular events associated
with wound healing and the development of chronic wounds in
RDEB skin, in part due to the lack of non-invasive protocols to
distinguish wound stage and prognosis of healing.
To understand molecular networks controlling wound healing
in RDEB skin, we developed a non-invasive approach for sampling
and analysis of inflammatory and immune activities at wound sites
using wound-covering bandages recovered from skin of RDEB
patients. This study highlights inflammatory and immune activi-
ties in RDEB wounds, thus providing potential markers of disease
activity and treatment effect.
2. Materials and methods
More detailed methods are described in Supplementary
Materials and Methods.
2.1. Subjects and samples
All patients received counseling pertaining to the study, and
written informed consents were obtained from all patients or their
legal guardians. Totally, seventy-six wound-covering bandages
were collected from early (1–5 days old; n = 22), established (1
week old; n = 23; 2 weeks old; n = 9) and chronic (3 weeks old; n =
22) wounds.
2.2. Collection and preparation of wound-covering bandages
Non-occlusive wound dressings (40  40 mm2) were
removed from the center of the wounds and placed in ice-cold
DMEM transport media (Corning, Corning, NY) supplemented
with 0.5 % Fetal Bovine Serum (FBS) (R&D Systems, Minneapolis,
MN), antibiotics (Primocin; Invivogen, San Diego, CA), and
proteinase inhibitors (Pierce, ThermoFisher, Waltham, MA).
Bandages containing ointments were excluded. All wounds had
no documented active bacterial infections. Cellular and soluble
components were recovered from bandages within 2448 h after
collection.
Fig.1. FACS-based analysis of bandage-recovered cellular constituents of RDEB wounds. (a) Scatter plot evaluation of cellular populations. Roman numerals mark populations
of distinct size and complexity. Percentage of viable cells recovered from bandages is shown in the upper left quadrants of the viability plot. (b) Dot-plot evaluation of
bandage-recovered cells expressing specific leukocytic markers, as indicated below the plots. Each dot represents an average of duplicate measures per individual sample.
Number of dots corresponds to a number of bandages used in the analysis. Annotated bars show mean percentages of marker-specific cells. Representative scatter plots with
outlined marker-specific populations are shown below the dot plots. (c) Columns showing mean percentages of marker-specific populations  SD defined by staining with
subset-specific markers shown on and under the columns. (d) Representative scatter plots showing distribution and percentages (upper right quadrant) of specific subsets in
bandage-recovered leukocytes. Detected antigens are shown to the left and under the corresponding plots. In all scatter plots, detected antigens are shown on axes.
Percentages of double-positive cells are shown in upper right quadrants.
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2.3. Recovery of cellular bandage-derived components
Biological material from bandages was removed with cell
scrapers and suspended in transport media. Clarified cell pellets
were washed with Phosphate Buffered Saline (PBS) and resus-
pended in DMEM media containing 10 % FBS and Primocin. Cell
viability was assessed by FACS using Guava ViaCount reagent
(Millipore, Burlington, MA) on the Guava EasyCyte system
(Millipore).
2.4. Soluble bandage-derived components
Bandage transport media was collected from pelleted cells and
clarified using sequential filtration on 1 mm and 0.22 mm filters.
Media was separated into high molecular weight (HMW) and low
molecular weight (LMW) fractions on Ultracel-100 K and Ultracel-
3 K concentration units (Millipore).
2.5. FACS-based immuno-phenotyping of bandage-derived leukocytes
About 5  104 cells per sample were incubated with
fluorophore-labeled leukocyte marker-specific antibodies (BioL-
egend, San Diego, CA) (Table S1). FACS was done on Guava EasyCyte
System and analyzed using GuavaSoft 2.7 software (Millipore).
Gating of specific population was based on forward versus side
scatter or labeling of cells with population-specific antibodies.
2.6. ELISA-based quantitation of cytokine release
Single-Analyte Quantikine ELISA (MMP2, MMP9, TIMP-1, IL-2,
IL-6, CXCL8, and TGFβ;
R&D Systems) was performed according to manufacturer
protocol.
2.7. Immunofluorescence analyses
Healthy and RDEB skin samples were embedded in Optimal
Cutting Temperature (OCT) compound (Sakura Finetek USA, Inc.,
Torrance, CA), frozen, and cryosectioned. Seven-micron sections
fixed in 4 % paraformaldehyde were incubated with CD31
primary antibodies (BD Biosciences, San Jose, CA) following
detection of immunocomplexes with fluorophore-labeled sec-
ondary antibodies. Blood vessel density (BVD) was determined
by direct counting of CD31-positive blood vessels on at least 3
independent microscopic fields from 8 control and 23 RDEB
samples.
2.8. Statistical analysis
Comparison of the data was performed using Student 2-tailed t-
test. A P-value of < 0.05 was considered statistically significant.
Fig. 2. FACS analysis of specific cellular subsets in RDEB wounds. (a) Column charts and (b) representative density pots illustrating progressive accumulation of CD16+CD66b+
and CD11b+CD66b+ mature neutrophils and dissipation of CD11b+CD68+ macrophages in chronic wounds. (c) Column charts and (d) representative density plots illustrating
accumulation of CD11c+CD80+CD86+ APC in chronic wounds. (e) Column charts and (f, g) representative density pots depicting reduction of CD45RO+CD4+ and CD8+
peripheral memory T cells and accumulation of CD45RA+ effector T cells in chronic wounds. Wound type (early, established, chronic) is indicated in the key in panel (a). In all
column charts, detected antigens are shown below the columns. Y-axis: percent of double-positive cells. The data are presented as mean percentage  SD. Statistical
significance (p < 0.05) is indicated by asterisk. Number of analyzed bandages per wound type per combination of antigens is shown under the columns. In all scatter plots,
detected antigens are shown on axes. Percentages of double-positive cells are shown in upper right quadrants.
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3. Results
Invasive methods, such as skin punch biopsies, are not clinically
recommended for RDEB patients. For analysis of wound bed-
associated infiltrates, we established non-invasive sampling
approach utilizing wound-covering dressings. Cells isolated from
bandages, which stayed on the wounds for 2448 h, showed 3–4
distinct cell populations of varying sizes and complexity and an
average viability of 80 % (Fig. 1a). Cells from dry or more than 5-
day-old bandages showed decreased viability (less than 30 %), no
distinct cell populations (Fig. S1a, b), and were excluded from all
analyses. Initial fluorescence activated cell sorting (FACS)-based
immuno-phenotyping showed that on average 75 % of recovered
cells were represented by CD45+ cells (Fig. 1b). Gating on specific
populations showed that population I and IV were mostly
comprised of CD45+ leukocytes, presumably myeloid and T cells,
respectively. The remaining 25 % of CD45 bandage-associated
cells were mostly represented by fully differentiated and
anucleated keratinocytes (population II) (Fig. S1c). Bandage-
recovered cells associated with population III were able to produce
fibroblastic cultures, which differentiate into alpha smooth muscle
actin (αSMA) expressing cells when maintained as a sparse culture
(Fig. S1d–g). Further immuno-phenotyping showed that about 47
% of leukocytes expressed CD11b myeloid cell marker, 45 % of
CD11c antigen presenting cell (APC) marker, and about 10 %
expressed CD8 and CD4 T cell markers (Fig. 1b). About 50 % of
CD11b+ cells expressed CD16 myeloid cell marker, and about 70 %
of these cells were positive for CD66b granulocyte neutrophil
activation marker (Fig. 1c, d). In addition, 49 % of CD11c+ expressed
CD207 (Langerin) marker of Langerhans cells (LC). On average, 70 %
of all CD11c+ cells expressed CD80 APC activation marker, 50 % of
which co-express CD86. Activated/effector populations were noted
in CD4+ and CD8+ bandage-derived T cells. Cumulative data showed
that about 40 % of CD4+ and 25 % of CD8+ T cells express CD45RO
marker of antigen-experienced effector memory T cells (Fig. 1c, d).
About 60 % of CD4+ and 75 % of CD8+ cells expressed CD45RA
marker of naïve and effector cells (data not shown).
Considering broad distribution of CD11b+, CD11c+, and T cell
populations (Fig. 1b), we further investigated whether percentages
of specific cell types correlate with wound progression. All wounds
were categorized into three groups, early, established and chronic,
as defined by the age of the wounds. FACS-based evaluation
showed a progressive and significant accumulation of
CD11b+CD66b+ cells at chronic wounds. In early wounds,
neutrophils represented about 20 % of total leukocytes, whereas
in 3 weeks and older wounds these cells represented up to 90 % of
total leukocytes (Fig. 2a, b). Further immuno-phenotyping
confirmed that this population is represented by CD16+CD66b+
mature neutrophils (Fig. 2b). Accumulation of neutrophils in
chronic wounds could be associated with dysfunctional healing
and correlate with the loss of complement component 5a C5aR1
and C5L2 receptors [7]. However, examination of 5a C5aR1 and
C5L2 expression on CD66b+ cells showed no significant reduction
of both receptors on neutrophils recovered from either early or
chronic wounds. FACS-based evaluation showed that an average 60
% and 20 % of CD66b+ neutrophils express C5L2 and C5aR1
receptors, respectively, in all wound types (Fig. 2a). Interestingly,
CD11b+CD68+ macrophages were present at low fractions in all
examined wounds (Fig. 2a). Overall percentage of macrophages
among wound-bed associated leukocytes was higher in estab-
lished wounds (up to 10 %) but dropped significantly down to 2.5 %
in chronic wounds (Fig. 2a).
All CD11c+ APC were equally represented by CD207+ LC and
CD207 DC populations in all wound types (Fig. 2c). Intriguingly,
progression of wounds from early to chronic was associated with
the accumulation of CD11c+CD80+ activated APC. Early wounds
contained about 30 % of CD80+ APC, whereas chronic wounds
showed up to 70 % of activated APC (Fig. 2c, d). In all wound types,
there were no significant changes in CD207+ LC activation. These
findings were further confirmed by evaluation of both CD80 and
CD86 activation markers. About 17 % of total APC expressed both
makers in early and established wounds, while this percentage was
increased up to 35 % in chronic wounds. These data showed that
accumulation of the activated APC in chronic wounds is mostly due
Fig. 3. FACS analysis of chemokine receptors on RDEB wound-associated leukocytes.
(a) Column charts and representative profiles depicting expression of CXCR2 and CCR2 chemokine receptors on CD16+, CD66b+, and CD11b+myeloid cell populations. Detected
chemokine receptors are on the columns. (b) Column charts and representative profiles depicting CCR2 and CXCR2 expression on CD16+CD66b+ mature neutrophils in early,
established and chronic wounds. (c) Column charts illustrating expression of CCR4 and CCR5 chemokine receptors on a total population of wound-associated T cells and on
CD4+ and CD8+ T cells in early, established and chronic wounds. (d) Representative density plots depicting CCR4 and CCR5 expression of CD4 and CD8-gated T cell populations
in early, established and chronic wounds. In all column charts, the data are presented as mean percentage  SD. Statistical significance (p < 0.05) is indicated by asterisk.
Number of analyzed bandages per wound type per combination of antigens is shown under the columns. In all scatter plots, detected antigens are shown on axes. Percentages
of double-positive cells are shown in upper right quadrants.
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to the accumulation of activated DC. Evaluation of the T cells
showed that early wounds were populated with CD4+CD45RO+
effector memory and CD4+CD45RA+ naïve T cells (Fig. 2e–g).
Progression of wounds was associated with a substantial decrease
of the effector memory T cells and increase of the CD4+CD45RA+
effector T cells in chronic wounds (Fig. 2c). Similar trend was
observed for CD8+ T cells.
We previously reported that high levels of CCR2, CXCR1, CXCR2,
and CCR4 ligands dominate early RDEB blisters, and that these
chemokine receptors support directional migration of leukocytes
in vitro [8]. Evaluation of these receptors on bandage-derived
leukocytes showed that about 80 % of cells expressed both CCR2
and CXCR2 receptors (Fig. 3a, b). Most consistent receptor
expression was detected on CD11b-gated cell population. Sub-
stantially greater variations in percentages of CCR2+ cells were
seen in CD66b-gated cells. Nevertheless, analysis of CD66b+
population showed a significant accumulation of both CCR2+
and CXCR2+ cells in established and chronic wounds (Fig. 3a, b).
Although such accumulation was detected in a rather large number
of samples (n = 9 per wound type), several samples collected from
one patient showed a substantially low number of CCR2+ and
CXCR2+ granulocytes in all wound types and, particularly, in
chronic wounds (Fig. S2).
Previously, we also reported that CCR4+ and CCR5+ lymphocytes
migrate in response to RDEB-derived blister fluids in vitro [8]. As an
accumulation of the activated/effector T cells was observed in
chronic wounds, we evaluated whether these chemokine receptors
could facilitate migration of the T cells to the wound bed. When
assessing a T-cell gated population, about 83 % and 91 % of cells
were identified as CCR4+ and CCR5+, respectively. Percentages of
CCR5+ T cells (both CD4+ and CD8+) were consistently high in all
wound types (Fig. 3c, d). In early wounds, about 70 % of CD4+ and
86 % of CD8+ T cells express CCR4 on cell surface. In established and
chronic wounds, these percentages were significantly increased up
to 86 % and 91 %, respectively (Fig. 3c, d).
Wound repair results from a highly complex interaction of
cellular and biochemical events. To date, many investigations
described proteins and signaling molecules that contribute to the
disordered healing, as for example in diabetic foot ulcers (DFU)
[9,10], yet, these molecular networks remain poorly defined in
RDEB wounds. Considering a known contribution of matrix
metalloproteinases (MMPs) to chronic wound pathogenesis [11],
we assessed MMP2 and MMP9 in a low molecular weight (LMW)
fraction. Quantitative cytokine-specific ELISA showed that both
MMPs are present at wound sites, and that concentration of MMP9
is 5–10 times greater than MMP2. Moreover, significantly higher
MMP9 levels were detected in established and chronic wounds as
compared to early lesions (Fig. 4a). Consistent with our prior
studies [8], we also detected low levels of tissue inhibitor of
metalloproteinases 1 (TIMP-1) in all wounds. When evaluating
MMP9/TIMP-1 ratio, another predictor of wound healing [12], we
found that early RDEB wounds had the highest MMP9/TIMP-1 ratio
(Fig. 4b). Considering that mature neutrophils produce MMPs and
other matrix remodeling enzymes, we also assessed cathepsin G
content. Concentration of this serine protease was significantly
higher in chronic wounds as compared to early wounds (Fig. 4c).
Healing of skin wounds depends on different biochemical
mediators such as growth factors and cytokines. To evaluate
suitability of bandage-derived samples for the analysis of these
soluble factors, we also measured interleukin 6 (IL-6) and IL-2, two
cytokines known to contribute to wound healing. ELISA-based
quantitation showed that both interleukins are present in all
examined wounds with IL-6 levels in nanogram range and IL-2 in
picogram range (Fig. 4d). No significant difference was detected
Fig. 4. Evaluation of bandage-recovered soluble factors in early, established and chronic wounds and analysis of angiogenesis in RDEB skin samples. (a) ELISA-based
quantitation of MMP2, MMP9, and TIMP-1 in a soluble fraction recovered from bandages covering early, established, and chronic wounds. Data are presented as a mean
concentration (ng/mL) of triplicate measures  SD. (b) Column chart depicting average MMP9/TIMP-1 ratio in early, established and chronic wounds. Data are presented as
fold difference  SD. (c) Column charts showing cathepsin G concentration in early, established and chronic wounds as determined by cathepsin G assay. Data are resented as
mean concentration  SD. (d) ELISA-based quantitation of selected cytokines and growth factors (indicated below the columns) in early, established and chronic wounds (as
indicated in the key). Data are presented as mean concentration (pg/mL) SD. In all column charts, statistical significance (p < 0.05) is indicated by asterisk. At least, 4
independent samples per wound type per detected protein were used. (e) Representative micrographs illustrating elevated number of CD31+ blood vessels in RDEB intact
(undamaged) skin. Source of skin samples (genetically normal control and RDEB) are indicated above the micrographs. Red – CD31+ blood vessels; blue – DAPI nuclear
staining. The basement membrane zone is outlined by dotted line. Scale bar – 100 mm. (f) Analysis of blood vessel density (BVD) per section of the skin. Data are presented as
an average number of blood vessels per section  SD. Eight independent control and 23 RDEB samples were used for the assessment. Statistical significance (p < 0.05) is
indicated by asterisk.
T. Phillips, L. Huitema, R. Cepeda et al. / Journal of Dermatological Science 100 (2020) 209–216 213
between the cytokine levels in different wounds. Similarly, there
were no significant differences in soluble TGF-β and a pro-
inflammatory/pro-angiogenic chemokine CXCL8 (IL-8) in all
wound types. Assessment of vascular endothelial growth factor
(VEGF)-A), a known angiogenic factor which contributes to normal
wound healing [13], showed significant difference in chronic
wounds, as compared to early lesions (Fig. 4d).
Because excessive angiogenesis and elevated VEGF levels
contribute to hypertrophic scarring [14], we examined micro
vessel density (MVD) in biopsies obtained from 23 RDEB patients
and 8 controls. Indirect immunofluorescence detection of CD31+
blood vessels showed that RDEB skin has more blood capillaries
than normal skin (Fig. 4e, f). Together with high level of pro-
angiogenic CXCL8 and elevated VEGF-A in chronic wounds, these
findings suggest that increased angiogenesis in RDEB skin may
contribute to poor wound healing and hypertrophic scarring of the
skin.
4. Discussion
The concept of acute vs. chronic wounds has changed over the
past few years. Generally, it was accepted that a 21-day arbitrary
limit for re-epithelization defined acute wounds. Currently,
chronic wounds could be defined as not healing at the expected
rate, or stalled in one of the wound healing phases. However, for
various disorders and diseases, including RDEB, “expected rate” is
not well-defined. Molecular and cellular networks associated with
development of poorly healing/chronic wounds in RDEB remain
uncharacterized, and there are no reliable biomarkers to evaluate
or predict the fate of RDEB wounds. Because punch biopsies are not
medically advisable for RDEB patients, we tested whether wound-
covering dressings could be used for a non-invasive recovery of
both cellular and molecular constituents of the RDEB wounds. In
the past, biopsies of the skin adjacent to wound sites, wound
debridement, wound exudates, peripheral blood, and smears from
wound bed were used for biochemical assessment of wound status
[9,15–18]. Although valuable, all these approaches have method-
specific limitations. In comparison, our approach allows recovery
of cellular and molecular components directly from the wound,
immuno-phenotyping of wound-derived cells, isolation of specific
cell types for functional assays, and establishment of selected cell
lines.
Evaluation of cellular components showed that the majority of
wound bed-associated cells are represented by various leuko-
cytes, and fully differentiated keratinocytes and fibroblastic cells.
Considering a crucial role of innate immunity in wound healing, it
was not surprising that the majority of wound-associated
leukocytes were represented by CD11b+ myeloid cells. However,
most of CD11b+ cells, particularly in chronic wounds, were
identified as CD16+CD66b+ mature neutrophils. As neutrophils
play an important role on early stages of wound healing and are
usually cleared at the end of the inflammatory stage [19], their
accumulation at the RDEB wounds indicates on deregulation of
the early inflammatory stage. At present, the cause for such
deregulation remains unknown. Nevertheless, sustained recruit-
ment and predominance of activated neutrophils in chronic RDEB
suggest that these wounds could be similar to the lesions of other
neutrophilic dermatoses, such as pyoderma gangrenosum (PG)
[20]. Although further comparative evaluation of soluble factors
affecting neutrophilic infiltrates in RDEB and PG are required, it is
plausible that treatments with anakinra or canakinumab that
were successful in treating PG [21–24] or topical steroids could be
used for management and treatment of chronic RDEB wounds.
Based on recent animal data showing partly impaired macro-
phage response in DEB mice [25] and our data showing a low
percentage of CD11b+CD68+ macrophages in all types of RDEB
wounds, it is also plausible that macrophages cannot eliminate
neutrophils from the wound bed at the end of the inflammatory
phase. Down-modulation of C5aR1 expression on CD66b+
neutrophils in chronic wounds may also indicate that neutrophils
have reduced ability to clear bacterial infection [7]. Although our
current analysis did not show any significant changes in receptor
expression on CD66b+ neutrophils in different wound types, it is
possible that relatively low percentage (up to 30 %) of
C5aR1+CD66b+ cells could implicate on neutrophil’s functional
activity. Although a more rigorous analysis is required, persistent
accumulation of mature neutrophils in chronic RDEB wounds
indirectly supports this notion.
Independently of neutrophil’s functional status, our current
data demonstrated that constitutive recruitment of myeloid cells
and neutrophils to RDEB wounds could be mediated by CCR2/
CXCR2-driven chemotaxis. These findings are consistent with our
prior data showing an abundance of CCR2/CXCR2 ligands in early
RDEB lesions [8]. Although the source of these ligands in early and
chronic RDEB wounds remains undefined, it is reasonable that
systemic or localized blocking of CCR2 and/or CXCR2 receptors
using small molecule inhibitors [26,27] could reduce neutrophil-
associated detrimental effects and accelerate wound closure.
An accumulation of neutrophils in established and chronic
RDEB wounds was accompanied by the elevated levels of MMP9
and cathepsin G. These findings correlate extremely well with
prior data showing that increased MMP9 levels can predict poor
wound healing in DFU [9,12]. An imbalance in MMP9 and TIMP-1
proteins results in excessive ECM degradation and higher MMP9/
TIMP-1 ratio defines poor wound healing [28]. Our data showing
that ratio in early RDEB wounds (29.6  3.1) is compatible with
that in sever neuropathic DFU (34.81  12.87) [12] suggest that
healing capacity in 1–5 days old lesions is already diminished.
Although insignificant increase in TIMP-1 levels was detected in
established and chronic wounds, its overall level remained low,
and MMP9/TIMP-1 ratio (11.4  3.2) remained compatible with
unhealed DFU (18.88  6.8) [12]. Similarly, high activity of
cathepsin G in chronic wounds suggests that this protease
alongside with MMP9 and other enzymes degrades multiple
fibrillar collagen and extracellular matrix components, thus,
preventing migration of keratinocytes and re-epithelialization of
wounds. Although further longitudinal evaluation of these
enzymes will be necessary, it is likely that targeted inhibition
of matrix remodeling enzymes could be a viable approach to
enhance RDEB wound healing.
Our analysis also revealed an accumulation of activated
CD80+CD86+ DC in chronic wounds with both markers expressed
on up to 50 % of all CD11c+ cells. These findings suggest an on-going
acquisition of antigens by the APC, and activation of the adaptive
immune response. Although CD80 and CD86 molecules can
substitute for each other in the initial activation of resting CD4+
T cells, CD86 could be more important for initiating T-cell
responses, while CD80 could be more significant for their
maintenance [29]. Considering a frequent colonization of the
RDEB wounds with bacteria and fungi [6,30], it is possible that
wound-associated APC play an active role in acquisition of bacterial
and/or fungal antigens, T cell priming, and activation. This notion is
supported by the presence of effector memory (CD45RAC-
D45RO+) and naïve (CD45RA+CD45RO) T cells at early wounds
and accumulation of CD45RA+-effector T cells in chronic wounds.
Considering an increased percentage of CCR4+ T cells in advanced
wounds (Fig. 3) and an important role of this receptor in skin-
homing [31], it is plausible that CCR4 mediates recruitment of T
cells to the wounds.
It is well-established that RDEB wounds are prone to fibrotic
scarring in which TGF-β1 plays a major role [32]. However,
pathogenesis of hypertrophic RDEB scars could also depend on
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altered cytokine and chemokine signaling that supports inflam-
mation, elevated activity of matrix remodeling enzymes, and
misbalanced production of growth factors. By assessing selected
bandage-recovered soluble proteins (IL-2, IL-6, CXCL8, TGF-β1, and
VEGF-A), we found that IL-6 is present at a relatively high level in
RDEB wounds. These findings are in agreement with prior animal
and human studies showing that delays in diabetic wound healing
may be associated with increased IL-6 [33], and that IL-6 levels are
higher in human diabetic chronic wounds than in healing wounds
[34]. Considering animal data showing that IL-6 supplementation
is associated with enhanced leukocyte recruitment, collagen
production and angiogenesis [35], it is possible that high IL-6
levels in RDEB wounds create a favorable milieu for poor wound
healing. Additional studies will be necessary to evaluate the role of
this cytokine in RDEB pathology.
High levels of pro-antigenic CXCL8 in RDEB blister fluids [8],
elevated VEGF-A level in chronic wounds, and high vascularization
of the intact RDEB skin [36] suggest that there is excessive
angiogenesis in wounded RDEB skin. This characteristic sets RDEB
wounds apart from diabetic, pressure, and arterial ulcers, where
lack of angiogenesis, hypoxia and ischemia contribute to poor
healing. Because elevated angiogenesis was linked to fibrotic
scarring [14], it is plausible that angiogenesis contributes
pathogenic scarring of RDEB skin. These findings also suggest
that targeting of angiogenesis via treatment with interferon
alpha2b or bevacizumab, a humanized anti-VEGF antibody used
to treat various malignancies, may reduce hypertrophic scarring
and improve healing of RDEB wounds [37,38].
In summary, presented cross-sectional evaluation showed that
progression of early wounds to chronic state is associated with the
elevated infiltration with mature neutrophils, significant reduction
of macrophages, and activation of APC- and T cell-mediated
adoptive immunity. Also, our data showed that excessive,
neutrophil-derived matrix remodeling enzymes, MMP9 and
cathepsin G, could prevent wound healing, whereas elevated
levels of VEGF-A and higher vascular density in RDEB skin and
wounds may support inflammation and negatively affect wound
healing.
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